The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 03, 2025

Filed:

Sep. 20, 2019
Applicant:

Instutite of Science Tokyo, Tokyo, JP;

Inventor:

Hitoshi Okazawa, Tokyo, JP;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61P 25/28 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/24 (2013.01); A61K 39/3955 (2013.01); A61P 25/28 (2018.01); C07K 16/18 (2013.01); C12N 15/63 (2013.01); A61K 39/395 (2013.01); A61K 2039/54 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01);
Abstract

It is an object of the present invention to provide a human monoclonal antibody that has a high inhibitory activity on phosphorylation of Ser46 of human MARCKS and binds specifically to human HMGB1, and a pharmaceutical composition or the like for treating or preventing Alzheimer's disease, containing the antibody as an active component. A human monoclonal antibody that binds specifically to human HMGB1 and contains a heavy-chain CDR1, a heavy-chain CDR2, and a heavy-chain CDR3 consisting of specific amino acid sequences and a light-chain CDR1, a light-chain CDR2, and a light-chain CDR3 consisting of specific amino acid sequences is used. The human monoclonal antibody can also be used as a pharmaceutical composition for treating or preventing Alzheimer's disease.


Find Patent Forward Citations

Loading…